bpc-157 eds Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle BPC-157 – Mark Hyman, MD

2008, doi: 10.1038/onc.2008.247

As of June 2026, tesamorelin is FDA-approved only for HIV-associated lipodystrophy (sold as EGRIFTA WR and EGRIFTA SV), ipamorelin is not FDA-approved, and the blend is not FDA-approved

The medication is formulated in various strengths and vial sizes to accommodate physician determinations of patient need

In findings from a phase 2a trial that were presented at the American Diabetes Association Scientific Sessions and simultaneously published in The Lancet , 71% of adults receiving coadministered cagrilintide and semaglutide 2.4 mg, dubbed CagriSema (Novo Nordisk), lost at least 10% of their body weight, and 89% of adults achieved an HbA1c of less than 7% with the combination therapy